Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Daito Pharmaceutical Co., Ltd. ( (JP:4577) ) has provided an announcement.
Daito Pharmaceutical has signed a memorandum of understanding with Kyorin Pharmaceutical to transfer Kyorin’s generic drug operations, including subsidiary Kyorin Rimedio and two production plants, to a new joint venture, Pharmatech Co-creation Platform, Inc. Daito will form this JV with two partners, becoming the largest but non-controlling shareholder, and will contribute its API R&D, supply strength and quality systems to bolster the platform.
The move aligns with Daito’s DTP2027 medium-term plan, which emphasizes streamlining existing businesses, consolidating manufacturing and enhancing lifecycle management of products. By integrating upstream functions such as R&D, manufacturing and quality assurance, Daito aims to help resolve Japan’s chronic generic drug supply instability, reinforce its own CMO business base and potentially upgrade industry-wide resilience and competitiveness in generic pharmaceuticals.
Kyorin Rimedio, the core target company in the deal, generated annual sales above ¥30 billion but has seen pressure on profitability, highlighting structural challenges in the generic sector. Incorporating these assets into the new JV is expected to rationalize overlapping capacity across firms, support government policy on integrating manufacturing and marketing approvals, and strengthen the broader pharmaceutical supply chain for stakeholders across the market.
More about Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co., Ltd. is a Japan-based drug manufacturer specializing in active pharmaceutical ingredients and finished pharmaceutical products, with a growing focus on generic medicines. The company positions itself as an R&D-driven contract manufacturing organization, leveraging its long-standing FDA-certified quality standards and domestic API capabilities to support stable pharmaceutical supply in Japan.
Average Trading Volume: 90,139
Technical Sentiment Signal: Buy
Current Market Cap: Yen39.15B
For a thorough assessment of 4577 stock, go to TipRanks’ Stock Analysis page.